Navigation Links
Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University

UPPSALA, Sweden, January 13 /PRNewswire/ -- Beactica AB, the Swedish fragment-based drug discovery company, today announced a new research collaboration agreement with GE Healthcare (Chalfont St. Giles, UK), the world leading provider of molecular interaction analysis tools, and Uppsala University (Sweden). The collaboration combines Beactica's unique approach to fragment-based drug discovery and GE Healthcare's Biacore(TM) technology with enzymology expertise from Uppsala University.

(Logo: )

Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore(TM) surface plasmon resonance instruments and applications for fragment-based drug discovery. The project also aims to identify novel high-quality leads against a clinically important, undisclosed protein target from Beactica's discovery pipeline. Financial terms of the agreement were not disclosed.

"We look forward to deepening our relationship with GE Healthcare and Uppsala University," said Beactica's CEO, Dr Per Kallblad. "The Biacore technology is a core component of our kinetics-integrated lead discovery platform. Being an active part in the development of next - generation applications from GE Healthcare will enable us to stay at the forefront of our field."

About Beactica

Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. The company was spun out of Uppsala University in August 2006. As well as building collaborations with external companies, Beactica is progressing its own drug discovery programmes of small molecule therapeutics. For more information about Beactica, please visit

For further information, please contact Dr Per Kallblad, CEO Beactica, +46(0)18-560880.

SOURCE Beactica AB
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
2. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
3. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
4. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
5. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
6. ProUroCare Medical Inc. Announces Pricing of Equity Offering
7. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
8. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
9. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
10. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma Services ... investment of at least $15.8  Million to expand ... Wilmington, NC . The expansion will provide ... meet the growing demands of the pharmaceutical and ... site expansion will provide up to 40,000 square ...
(Date:11/25/2015)...  Henry Schein, Inc., the world,s largest provider of ... and animal health practitioners, will unveil at the Greater ... ConnectDental® Pavilion , which brings together for the first ... to help any practice or laboratory enter the digital ... schedule of experts appearing at the Pavilion. --> ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... The McHenry County law firm of Botto Gilbert Lancaster, ... Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant ... (2d) 130884WC. , According to court documents, Adcock testified that on May 10, 2010 ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) - Today, ... specializing in both surgical and non-surgical treatments, announced the expansion of his private ... Plastic Surgery. , Highly trained and nationally recognized for his natural approach, ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... provide scholarships for people struggling with eating disorders as a result of the ... second annual event, held at Fox Run Golf Club in Eureka, will help ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... that it has undertaken significant expansion of its current state of the art ... part of PharmaTech’s strategy to increase its manufacturing capacity as well as to ...
Breaking Medicine News(10 mins):